Ubrelvy for Migraine: What Does the Data Show?

Read the table honestly and two things are true at once. The difference from placebo was statistically significant across these outcomes — the medication does something real. And Ubrelvy does not make every migraine disappear: roughly one in five participants was completely pain-free at two hours, which means most were not. Pain relief — pain dropping to mild or none — was the more common outcome, at about 61–63%.

That is not a criticism of the drug; it is what acute migraine data look like across this whole field. It does mean that "it didn't completely fix my attack" is a common experience rather than a sign something went wrong.

What about women?

Migraine is substantially more common in women, and the trials reflect that: women made up approximately 88% of participants in one major phase 3 ubrogepant study. More recent pooled analyses found that women receiving ubrogepant had significant improvements compared with placebo.

What those data do not support is the claim that the medication works better in women. Current evidence does not establish a clinically meaningful difference in overall ubrogepant effectiveness between women and men — partly because relatively few men participated, which limits how confidently any comparison can be made. Heavily female trial populations tell you the evidence is well grounded in women, not that women respond more.

Does it work for migraines around your period?

This question matters, because attacks linked to the cycle are often described as longer, more severe and harder to treat. A post-hoc analysis examined women treating attacks occurring around menstruation and reported two-hour pain freedom of approximately 29–30% for perimenstrual attacks depending on dose. Overall, efficacy was similar for perimenstrual and non-perimenstrual attacks, and investigators found no new safety signals.

The qualifier is important. A post-hoc analysis looks back at subgroups within trials that were not designed from the outset to answer this question, so it is genuinely useful information but not the same as a dedicated menstrual-migraine trial. It supports reassurance rather than proving a distinct effect.

Why this matters during the menopause transition

Migraine patterns commonly change during perimenopause as ovarian hormone levels fluctuate — attacks can become more frequent, more severe or simply less predictable, which we cover in why migraines get worse during menopause and migraine and hormone therapy. When attacks change, women often find themselves reaching for acute treatment more often — which is exactly when it helps to understand what the evidence behind each option actually says.

To be explicit: ubrogepant does not treat menopause, hormonal fluctuation or vasomotor symptoms. It treats migraine attacks. Its relevance here is timing and audience, not mechanism.

Two related points are worth keeping in view. Migraine with aura carries its own considerations for stroke risk and vascular health, particularly alongside other risk factors. And a headache that is genuinely new, different or escalating needs evaluation rather than a new abortive medication — as do other neurologic symptoms that arrive with it.

One more practical note: treating attacks very frequently can lead to medication overuse headache with several acute drug classes, and frequent attacks are usually a signal to discuss prevention rather than to keep escalating acute treatment. Our migraine decision guide walks through that conversation.